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Abstract
Objectives: Increasing physical activity reduces the risk of chronic illness including Type 2 diabetes, cardiovascular
disease and certain types of cancer. Lifestyle interventions can increase physical activity but few successfully engage
men. This study aims to investigate the 5 year cost-effectiveness of EuroFIT, a program to improve physical activity
tailored specifically for male football (soccer) fans compared to a no intervention comparison group.
Methods: We developed a Markov cohort model in which the impact of improving physical activity on five chronic
health conditions (colorectal cancer, Type 2 diabetes, coronary heart disease, stroke and depression) and mortality
was modelled. We estimated costs from a societal perspective and expressed benefits as quality adjusted life years
(QALYs). We obtained data from a 4-country (England, Netherlands, Portugal and Norway) pragmatic randomised
controlled trial evaluating EuroFIT, epidemiological and cohort studies, and meta-analyses. We performed
deterministic and probabilistic sensitivity analyses to assess the impact of uncertainty in the model’s parameter
values on the cost-effectiveness results. We used Monte Carlo simulations to estimate uncertainty and presented
this using cost-effectiveness acceptability curves (CEACs). We tested the robustness of the base case analysis using
five scenario analyses.
Results: Average costs over 5 years per person receiving EuroFIT were €14,663 and per person receiving no
intervention €14,598. Mean QALYs over 5 years were 4.05 per person for EuroFIT and 4.04 for no intervention. Thus,
the average incremental cost per person receiving EuroFIT was €65 compared to no intervention, while the average
QALY gain was 0.01. This resulted in an ICER of €5206 per QALY gained. CEACs show that the probability of EuroFIT
being cost-effective compared to no intervention is 0.53, 0.56 and 0.58 at thresholds of €10,000, €22,000 and €34,
000 per QALY gained, respectively. When using a time horizon of 10 years, the results suggest that EuroFIT is more
effective and less expensive compared to (i.e. dominant over) no intervention with a probability of cost-
effectiveness of 0.63 at a threshold of €22,000 per QALY gained.
Conclusions: We conclude the EuroFIT intervention is not cost-effective compared to no intervention over a period
of 5 years from a societal perspective, but is more effective and less expensive (i.e. dominant) after 10 years. We
thus suggest that EuroFIT can potentially improve public health in a cost-effective manner in the long term.
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Introduction
Physical activity decreases the risk of non-communicable
diseases such as coronary heart disease, Type 2 diabetes,
colorectal cancer, stroke and depression [1–4]. Some
benefits from physical activity occur quickly, such as re-
duced blood pressure, and improved sleep, cognitive
function and insulin sensitivity; others, such as increased
cardiorespiratory fitness, decreased depressive symp-
toms, and sustained reduction in blood pressure, only
accrue over months or years of increased physical activ-
ity [1]. International guidelines demonstrate that sub-
stantial health improvements can be achieved by
performing moderate to vigorous physical activity at
least 150min per week [5], which equates to at least 450
Metabolic Equivalent of Task minutes (MET-min) per
week [6]. Although estimates vary, many adults do not
meet these guidelines recommendations [7, 8], resulting
in substantial potentially preventable morbidity and
mortality [2, 5, 9, 10], as well as high societal and health-
care costs [11].
Increasing physical activity reduces the risk of chronic
illness including Type 2 diabetes, cardiovascular disease
and certain types of cancer [12–14]. Lifestyle interven-
tions can increase physical activity but few successfully
engage men. In response to this, Gray et al. developed a
program, Football Fans in Training (FFIT), tailored spe-
cifically to men. FFIT aimed to engage and support men
to lose weight through dietary change and physical activ-
ity by working with predominant constructions of mas-
culinity [15–17]. Based on the results of a pragmatic
randomised controlled trial (RCT), FFIT participants lost
more weight over 12 months than control participants
(mean difference in percentage weight loss 4.36% (95%
confidence interval (CI) 3.64 to 5.08) [17]. Moreover,
weight loss was sustained over 3.5 years of follow-up
(mean percentage weight loss from baseline 2.36% (95%
CI 1.41 to 3.31) [18].
Recently, the European Fans in Training (EuroFIT)
lifestyle change program was developed. The EuroFIT
program built on the FFIT program, but shifted the
focus of the program from weight loss to improving
physical activity and reducing sedentary behaviour.
EuroFIT was rigorously evaluated in a 4-country RCT
[19]. While the EuroFIT program successfully increased
the number of daily steps at 12 months, there was no
difference in sedentary time between the two groups
[20]. However, improvements were observed in second-
ary outcomes, including body weight, the proportion of
participants with a BMI less than 30 kg/m2, waist cir-
cumference, well-being, self-esteem and vitality, and bio-
markers of cardiovascular health (i.e. systolic and
diastolic blood pressure, fasting insulin and fasting tri-
glycerides). The within-trial cost-effectiveness analysis
showed that EuroFIT was not cost-effective compared to
a waitlist condition at 12 months follow-up for quality
adjusted life years (QALYs) [20]. However, if the ob-
served improvements in physical activity are sustained
over time, it is possible that EuroFIT is cost-effective
with regard to QALYs in the long term. Because the
waiting list comparison group received the EuroFIT pro-
gram after conclusion of the RCT, longer follow-up
within the RCT was unfeasible. Therefore, we used a
Markov cohort model to estimate the five-year cost-
effectiveness of the EuroFIT program compared to no
intervention. This is one of the first longer-term cost-
effectiveness studies evaluating a physical activity pro-
gram specifically tailored to men.
Methods
Design
We developed a Markov cohort model with a time hori-
zon of 5 years to estimate the cost-effectiveness of the
EuroFIT program from a societal perspective [19]. We
chose to use a Markov model due to its flexibility and its
ability to handle multiple possible outcomes [21]. We es-
timated transition probabilities, costs and utilities using
data from both the previously conducted EuroFIT RCT
and the literature.
The EuroFIT RCT
The EuroFIT RCT was conducted during 2016 and 2017
in England, The Netherlands, Norway and Portugal. Eth-
ics committees in each of the four countries have ap-
proved the study protocol [19]. The RCT was registered
with ISRCTN number 81935608.
Details of the EuroFIT RCT can be found in Van
Nassau et al. [19] and Wyke et al. [20]. In summary, 15
professional football clubs in England, the Netherlands,
Norway, and Portugal recruited 1113 men aged 30–65
with self-reported body mass index (BMI) ≥27 kg/m2
into the trial using any of social media posting, email in-
vitations to club members, and local press coverage. We
describe baseline characteristics of the participating men
in Supplementary Table 1.
Interventions
We designed the EuroFIT program to support men in
becoming more physically active. A detailed description
of the EuroFIT intervention is available in Van Nassau
et al. [19] and Van de Glind et al. [22]. Briefly, the Euro-
FIT intervention consisted of 12 weekly sessions in
groups of 15 to 20 men. Sessions lasted for 90 min, and
combined classroom discussions with group-based phys-
ical activities tailored to the ability of the participants.
Club coaches were trained to create a positive motiv-
ational climate tailored specifically to men while deliver-
ing the intervention. Coaches also taught participants to
choose from a ‘toolbox’ of behavior change techniques,
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and emphasized personally-relevant benefits of behavior
change such as being better able to fulfil valued activities
and roles.
The comparison group in the RCT was on a waiting
list for the 12months of the RCT. Subsequently, partici-
pants in the comparison group were offered the EuroFIT
intervention. However, for the current paper we as-
sumed that they received no intervention during the
time horizon of the model. Thus, the control group con-
stitutes a no intervention comparison group.
Model structure and population
We implemented the Markov model in R software. We
based the model on previously published physical activ-
ity models [23–27] and extended it with a depression
health state, as there is evidence of depression being as-
sociated with lack of physical activity [28, 29]. The Mar-
kov model comprised nine mutually exclusive health
states. Three health states described the activity levels:
physically inactive, moderately active and recommended
level of physical activity. Five health states covered five
health conditions associated with a lack of physical activ-
ity: colorectal cancer, coronary heart diseases, stroke,
Type 2 diabetes and depression. The absorbing ninth
state was death. Figure 1 shows the structure of the
Markov model.
The target population was the same as the participants
of the EuroFIT RCT. Apart from having a BMI of 27 or
more, we assumed the population otherwise to be in
good health, which was defined as the absence of any of
the five health conditions included in the model. We de-
termined the proportion of participants starting in each
activity level based on the proportion of participants
meeting inactive (17.5%), moderately active (10.5%) and
recommended activity (72.0%) thresholds at baseline in
the EuroFIT RCT. At the end of each cycle, participants
could remain in their assigned physical activity category,
or move to a different category of physical activity, a
health condition or death. The cycle length of the model
was 1 year. Thus, we assumed that transitions between
the different states of the Markov model occurred yearly.
We calculated expected costs and QALYs over a time
span of 5 years. In the base case analysis, we assumed
that the beneficial effect of EuroFIT compared to no
intervention on physical activity over 12 months
remained stable for the 5 years of the model. We tested
this assumption in one of the sensitivity analyses.
Model input parameters
Table 1 presents the parameters used in the Markov
model. As a first line strategy to retrieve information on
the association between physical activity levels and indi-
viduals’ health, we used the 2018 Physical Activity
Fig. 1 Structure of the Markov model. CHD = Coronary Heart Disease
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Table 1 Model input parameters
PARAMETERS FOR THE BASE CASE ANALYSIS
Values* Distribution for
probabilistic
sensitivity
analysis
Source
Physical activity (transition probabilities at the end of each cycle
of 12months)
EuroFIT
Inactive to
Inactive
0.18 Beta (α = 4.0,
β = 17.0)
EuroFIT RCT [20]
Inactive to
Moderately
active
0.054 Beta (α = 0.34,
β = 5.7)
EuroFIT RCT [20]
Inactive to
Recommended
activity
0.71 Beta (α = 59.4,
β = 19.6)
EuroFIT RCT [20]
Moderately
active to
Moderately
active
0.042 Beta (α = 0.09,
β = 1.9)
EuroFIT RCT [20]
Moderately
active to Inactive
0.085 Beta (α = 0.44,
β = 4.56)
EuroFIT RCT [20]
Moderately
active to
Recommended
activity
0.82 Beta (α = 33.8,
β = 5.2)
EuroFIT RCT [20]
Recommended
activity to
Recommended
Activity
0.89 Beta (α = 357.9,
β = 26.1)
EuroFIT RCT [20]
Recommended
activity to
Inactive
0.042 Beta (α = 0.83,
β = 18.2)
EuroFIT RCT [20]
Recommended
activity to
Moderately
active
0.023 Beta (α = 0.24,
β = 9.8)
EuroFIT RCT [20]
No intervention
Inactive to
Inactive
0.33 Beta (α = 11.5,
β = 21.5)
EuroFIT RCT [20]
Inactive to
Moderately
active
0.12 Beta (α = 1.6,
β = 10.4)
EuroFIT RCT [20]
Inactive to
Recommended
activity
0.49 Beta (α = 25.0,
β = 23.0)
EuroFIT RCT [20]
Moderately
active to
Moderately
active
0.17 Beta (α = 1.5,
β = 6.6)
EuroFIT RCT [20]
Moderately
active to Inactive
0.19 Beta (α = 2.1,
β = 8.0)
EuroFIT RCT [20]
Moderately
active to
Recommended
activity
0.58 Beta (α = 16.6,
β = 10.4)
EuroFIT RCT [20]
Table 1 Model input parameters (Continued)
PARAMETERS FOR THE BASE CASE ANALYSIS
Values* Distribution for
probabilistic
sensitivity
analysis
Source
Recommended
activity to
Recommended
Activity
0.80 Beta (α = 290.7,
β = 58.3)
EuroFIT RCT [20]
Recommended
activity to
Inactive
0.10 Beta (α = 4.2,
β = 37.8)
EuroFIT RCT [20]
Recommended
activity to
Moderately
active
0.064 Beta (α = 1.9,
β = 26.1)
EuroFIT RCT [20]
Health conditions (transition probabilities at the end of each cycle
of 12months)
Inactive to
colorectal cancer
0.015 Fixed COSM study [30, 31]
Inactive to heart
diseases
0.011 Fixed Meta-analysis; SALLS
study [30, 32–34]
Inactive to Type
2 diabetes
0.005 Fixed EPIC-Interact study and
epidemiological study
[33, 35, 36]
Inactive to
stroke
0.0046 Fixed ARIC study [37]
Inactive to
depression
0.010 Fixed Meta-analysis; Health
survey for England and
Scotland [34, 35, 38]
Moderately
active to
colorectal cancer
0.011 Fixed COSM study [30, 31]
Moderately
active to heart
disease
0.009 Fixed Meta-analysis; SALLS
study [30, 32–34]
Moderately
active to Type 2
diabetes
0.0038 Fixed EPIC-Interact study;
epidemiological study
[33, 35, 36]
Moderately
active to stroke
0.0033 Fixed ARIC study [37]
Moderately
active to
depression
0.0094 Fixed Meta-analysis; Health
survey for England and
Scotland [34, 35, 38]
Recommended
activity to
colorectal cancer
0.0096 Fixed COSM study [30, 31]
Recommended
activity to heart
disease
0.008 Fixed Meta-analysis; SALLS
study [30, 32–34]
Recommended
activity to Type
2 diabetes
0.0033 Fixed EPIC-Interact study;
epidemiological study
[33, 35, 36]
Recommended
activity to stroke
0.0029 Fixed ARIC study [37]
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Guidelines Advisory Committee Scientific Report [6].
The report includes the broadest systematic literature
review available on the association between physical ac-
tivity and adverse outcomes, including risk of
Table 1 Model input parameters (Continued)
PARAMETERS FOR THE BASE CASE ANALYSIS
Values* Distribution for
probabilistic
sensitivity
analysis
Source
Recommended
activity to
depression
0.0092 Fixed Meta-analysis; Health
survey for England and
Scotland [34, 38, 39]
Mortality (transition probabilities at the end of each cycle of 12 months)
Inactive to death 0.016 Fixed Meta-analysis;
epidemiological study
[73, 74, 75, 76]
Moderately
active to death
0.012 Fixed Meta-analysis;
epidemiological study
[73, 74, 75, 76]
Recommended
activity to death
0.010 Fixed Meta-analysis;
epidemiological study
[73, 74, 75, 76]
Colorectal
cancer to death
0.092 Fixed International Cancer
Benchmarking
partnership registries
[40]
Coronary heart
disease to death
0.002 Fixed WONDER registry [41]
Type 2 diabetes
to death
0.015 Fixed ZODIAC study [42]
Stroke to death 0.400 Fixed MONICA registry [43]
Depression to
death
0.030 Fixed STIRLING registry [44]
Utility values
Inactive – Base
case
0.909 Beta (α = 3.0,
β = 0.38)
EuroFIT RCT [20]
Moderately
active – Base
case
0.919 Beta (α = 5.1,
β = 0.51)
EuroFIT RCT [20]
Recommended
activity – Base
case
0.922 Beta (α = 5.1,
β = 0.43)
EuroFIT RCT [20]
Colorectal
cancer
0.786 Fixed Systematic review [45]
Coronary hearth
disease
0.735 Fixed Longitudinal survey
[46]
Stroke 0.62 Fixed Longitudinal survey
[47]
Type 2 diabetes 0.785 Fixed Systematic review [48]
Depression 0.57 Fixed Systematic review [49]
Annual costs per person according to the societal perspective (€ 2017)
Inactive 2436 Gamma
(shape = 0.19,
scale = 12,658)
EuroFIT RCT [20]
Moderately
active
1506 Gamma
(shape = 0.22,
scale = 6920)
EuroFIT RCT [20]
Recommended
activity
1997 Gamma
(shape = 0.24,
scale = 8222)
EuroFIT RCT [20]
Table 1 Model input parameters (Continued)
PARAMETERS FOR THE BASE CASE ANALYSIS
Values* Distribution for
probabilistic
sensitivity
analysis
Source
Colorectal
cancer
34,085 Fixed Cross sectional study;
Health insurance
registry [50, 51]
Coronary heart
disease
5239 Fixed Economic burden [52]
Type 2 diabetes 5907 Fixed Economic burden [53]
Stroke 24,979 Fixed Economic burden [54]
Depression 6819 Fixed Cost-effectiveness
analysis [55]
EuroFIT program 260 Fixed EuroFIT RCT [20]
PARAMETERS FOR THE SENSITIVITY ANALYSES
Utility values
Inactive –
Literature
utilities
0.80 Fixed Economic evaluation
[24]
Moderately
active –
Literature
utilities
0.87 Fixed Economic evaluation
[24]
Recommended
activity –
Literature
utilities
0.91 Fixed Economic evaluation
[24]
Annual costs per person according to the healthcare perspective
(€ 2017)
Inactive 1107 Gamma
(shape = 0.10,
scale = 10,924)
EuroFIT RCT [20]
Moderately
active
594 Gamma
(shape = 0.35,
scale = 1707)
EuroFIT RCT [20]
Recommended
activity
747 Gamma
(shape = 0.19,
scale = 4040)
EuroFIT RCT [20]
Colorectal
cancer
25,346 Fixed Cross sectional study;
Health insurance
registry [50, 51]
Coronary heart
disease
1954 Fixed Economic burden [52]
Type 2 diabetes 3089 Fixed Economic burden [53]
Stroke 18,750 Fixed Economic burden [54]
Depression 966 Fixed Cost-effectiveness
analysis [55]
*Values represent probabilities, mean utilities or mean costs
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cardiovascular disease, cancers and all-cause mortality.
As it does not specifically focus on the population inves-
tigated in EuroFIT, we used this review to identify stud-
ies including male individuals aged between 30 to 65
years.
To identify additional studies on the natural course of
physical activity, we conducted targeted literature
searches using PubMed, Web of Science and Google
Scholar. We only included studies written in English.
Whenever a study provided data that were relevant to
populate the model, we screened the reference list to
identify and retrieve additional evidence. We also con-
ducted targeted literature searches to retrieve informa-
tion on resource use and utilities associated with
physical activity levels. Whenever possible, we retrieved
evidence from studies conducted in European countries
related to a mainly Caucasian, male, overweight popula-
tion, aged between 30 and 65 years old. If these were not
available, we used comparable evidence from normal
weight individuals, from the USA, or for male popula-
tion of an older age as model inputs.
Physical activity
Table 1 presents the changes in self-reported physical
activity for the EuroFIT and no intervention groups. We
estimated yearly probabilities of transitioning between
physical activity levels or staying in the original activity
level using the EuroFIT pragmatic RCT [20] and made
them conditional on the transition probabilities of pro-
gressing to a condition or death. The EuroFIT RCT
assessed physical activity both objectively with the activ-
PAL monitor (model activPALTM micro; PAL Tech-
nologies Ltd., Glasgow, UK) and subjectively using the
self-reported International Physical Activity Question-
naire (IPAQ short form), which assesses walking, other
moderate intensity physical activity and vigorous inten-
sity physical activity [56]. Both measures of physical ac-
tivity improved in the EuroFIT arm of the RCT. We
used self-reported physical activity in our model for two
main reasons. First, although subjectively reported phys-
ical activity rates almost certainly over-estimate the ac-
tual level of physical activity, the current physical
activity guidelines are primarily built on epidemiologic
studies that used self-report measures. Secondly, there
are still too few studies that estimate the association be-
tween objective measures of physical activity and health.
We defined the three activity categories according to
the self-reported MET-min per week of the EuroFIT
participants. MET-min per week is an index capturing
the total amount of all physical activity, where one MET
is defined as the rate of energy expenditure at rest [5].
We classified participants reporting < 200 MET-min per
week as physically inactive, participants reporting be-
tween 200 and 450 MET-min per week as moderately
physically active, and participants reporting > 450 MET-
min per week as meeting desired levels of physical activ-
ity, according to physical activity guidelines [5, 6, 57].
We estimated the probability of moving to a higher or
lower physical activity category in the EuroFIT RCT for
the intervention and the comparison group separately as
the percentage of participants in one activity group at
baseline moving to a different activity group at 12
months follow up.
Health conditions and mortality
To estimate the yearly probability of developing each of
the five health conditions included in the model, we
used incidence and relative risk data from the literature.
To estimate the probability of death associated with the
five conditions, we used annual mortality rates based on
a particular condition. To estimate the probability of
death associated with different levels of physical activity,
we used mortality rates and relative risk data. The
sources are described in more detail in Table 1; they in-
cluded meta-analyses, epidemiological studies and regis-
tries [30–33, 35–44, 55, 57–60].
Utilities
We used QALYs as the effect measure in the cost-
effectiveness analysis. QALYs are calculated by multiply-
ing the time participants spend in a given health state
with a utility value that represents the health-related
quality of life (HRQoL) associated with that health state.
We obtained utility values for the inactive, moderately
active and recommended activity states from the Euro-
FIT RCT [20]. The EuroFIT RCT used the five level ver-
sion of the EuroQol questionnaire (EQ-5D) to estimate
utilities, which is the most widely used measure to do
this [61]. We obtained utilities for the chronic conditions
covered in the model from three systematic reviews and
two longitudinal studies [45–49].
Costs
We estimated costs of the EuroFIT program using a
bottom-up approach, and included costs of personnel re-
sponsible for preparation, coordination, administration,
recruitment and program delivery, and materials. We es-
timated costs generated in the different activity states
based on the EuroFIT RCT [20]. We obtained costs of
the conditions modelled from three economic burden
studies, one cross-sectional study, one registry study and
one economic evaluation [50–55]. In accordance with
the societal perspective employed in this study, we in-
cluded both healthcare costs and lost productivity costs.
We adjusted costs using the consumer price index to the
year 2017 [62] and, whenever needed, we converted
costs into Euros (€) for the year 2017 using purchasing
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power parities [63], as recommended in international
guidelines [21].
Cost-effectiveness analysis
We distributed a cohort of 10,000 participants in each of
the treatment arms over the three activity categories at
the start of the time horizon modelled. As recommended
by the National Institute for Health and Care Excellence
(NICE), we discounted costs and effects at 3.5% [64]. We
calculated incremental cost-effectiveness ratios (ICERs)
by dividing the difference in total costs between the
EuroFIT intervention and the comparison group by the
difference in total QALYs. We consider the intervention
cost-effective if the ICER is smaller than a pre-defined
willingness-to-pay threshold. For the current study, we
used the commonly accepted NICE threshold of £20,000
to £30,000 per QALY gained [64], which corresponds to
€22,000 to €34,000 per QALY gained.
Sensitivity analyses
Probabilistic sensitivity analyses
We performed a probabilistic sensitivity analysis (PSA)
for the base case analysis and each of the four scenario
analyses. For parameters that were directly observed in
the EuroFIT RCT, we estimated a sampling distribution
based on the variance around the point estimates for
these parameters. Next, we used Monte Carlo simulation
(25,000 simulations) to randomly select values from the
specified distributions. We used beta distributions for
transition probabilities, beta distributions for utilities
and gamma distributions for costs (Table 1). Using the
25,000 simulations, we estimated 95% credibility inter-
vals around incremental costs and QALYs based on the
2.5 and 97.5% percentiles. Finally, we estimated cost-
effectiveness acceptability curves (CEACs) to present the
probability of EuroFIT being cost-effective compared to
no intervention at different willingness to pay
thresholds.
Deterministic sensitivity analyses
We performed deterministic sensitivity analyses in which
the discount rates for costs and effects were varied (0
and 5%). This was undertaken for costs and effects sep-
arately, and for costs and effects simultaneously.
Scenario analyses
We tested the robustness of the base case findings by
performing four scenario analyses. For all scenarios, we
evaluated the deterministic impact on the ICER point es-
timate and the probabilistic impact on the probability of
cost-effectiveness at different willingness to pay ratios.
First, we extended the time horizon of the model to
10 years to assess longer term effects of the intervention
while assuming that the effect of EuroFIT was
maintained over a period of 10 years. Second, we ran the
model from the healthcare perspective, as this is pre-
ferred by health technology assessment bodies such as
NICE [64]. Third, we obtained utility values for the in-
active, moderately active and recommended activity
states from the literature, and specifically from a previ-
ously conducted economic evaluation of an intervention
to improve physical activity [24]. We did this sensitivity
analysis, because differences in utility values between
physical activity levels in the literature are larger than
the ones we found in the EuroFIT RCT. Fourth, we re-
ran the model while limiting the beneficial effect of
EuroFIT on physical activity to the first year, hence after
the first year the transition probabilities from the no
intervention group were used.
Results
Cost-effectiveness analysis
Table 2 reports the results of the base-case analysis.
Total costs for the EuroFIT group were €146,629,613
per 10,000 participants as compared to €145,975,002 in
the no intervention group. This resulted in an incremen-
tal cost for the cohort of €654,611, equivalent to €65 per
participant. QALYs in the EuroFIT group were 40,431
compared to 40,405 in the no intervention group, result-
ing in a small gain of 126 QALYs (+ 0.31%) in favour of
EuroFIT, which is equivalent to 0.013 QALYs gained per
participant. EuroFIT generates 195 QALYs more than
no intervention based on time spent in the health states
describing the physical activity levels (the ‘healthy’
states). In addition, the EuroFIT group generates 69
QALYs less than no intervention based on time spent in
the health states describing the associated health condi-
tions (the ‘disease’ states). The resulting ICER was €5206
per QALY gained for EuroFIT in comparison with no
intervention.
Probabilistic sensitivity analysis
Figure 2 presents the distribution of incremental cost-
effect pairs for the base case analysis based on the 25,
000 simulations in the probabilistic sensitivity analysis.
The cost-effectiveness plane shows that EuroFIT is more
effective and more costly than no intervention, and that
there is considerable uncertainty around the ICER.
From the CEAC (Fig. 3), it emerges that the probabil-
ity that EuroFIT is cost-effective compared with no
intervention, is 0.53 at a threshold of €10,000 per QALY.
This probability increases to 0.56 and 0.58 at thresholds
of €22,000 and €34,000 per QALY gained, respectively.
Sensitivity analyses
Deterministic sensitivity analyses
Figure 4 reports the results for the deterministic sensitiv-
ity analyses in which the discount rates were varied from
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the base case analysis. The figure shows that the effect
on the ICER point estimates was limited with impacts
ranging from − 35% (discount rate for costs and effects
0%) to 15% (discount rate for costs and effects 5%).
Scenario analyses
Figure 4 also presents the deterministic results of the
scenario analyses. When the time horizon of the model
was extended to 10 years, the ICER became negative due
to a negative difference in costs (−€2,595,287) and a
positive difference in QALYs gained (373 QALYs
gained), indicating that EuroFIT is dominant over no
intervention. Employing a healthcare perspective de-
creased the ICER by 24%. Using literature estimates for
the utilities associated with the different physical activity
levels resulted in 39,767 and 39,203 QALYs in the Euro-
FIT and no intervention group, respectively. Thus, the
total number of QALYs gained was 564 in the EuroFIT
group, or 0.056 QALY per participant. The ICER was
€1161 per QALY gained, indicating a decrease of 78%
Table 2 Cost effectiveness results for the base case and scenario analyses
Analysis Treatment
arm
Total costs (€
2017)
Total
QALYs
Incremental Cost Incremental
QALYs
ICER
Base case EuroFIT €146,629,613 40,531 €654,611 (−73,893,166; 81,741,624) 126 (−1999; 2527) 5206
No
intervention
€145,975,002 40,405
Healthcare perspective EuroFIT €72,489,139 40,531 €496,731 (−37,026,528; 35,107,767) 126 (− 2026; 2537) 3951
No
intervention
€71,992,408 40,405
Utility values from the literature EuroFIT €146,629,613 39,767 €654,611 (−73,893,166; 81,741,624) 564 (−68; 1106) 1161
No
intervention
€145,975,002 39,203
EuroFIT effectiveness lasts only 1
year
EuroFIT €147,631,100 40,427 €1,759,289 (−19,869,112; 25,189,
547)
52 (− 555; 725) 33,997
No
intervention
€145,871,811 40,375
Time horizon 10 years EuroFIT €303,622,814 71,010 -€2,595,287 (−128,814,119; 137,269,
728)
373 (− 3254; 4534) Dominant
No
intervention
€306,218,101 70,636
QALY Quality-Adjusted Life-Year, ICER Incremental Cost-Effectiveness Ratio
Fig. 2 Cost-effectiveness plane for the base case analysis. WTP =Willingness-To-Pay; QALY = Quality-Adjusted Life-Year
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compared with the base case analysis. The assumption
that the effect of EuroFIT lasted only for 1 year, resulted
in an increase of the difference in costs between Euro-
FIT and no intervention (€1,759,289) and a decrease in
QALYs gained (52 QALYs gained). As a result, the ICER
increased by 553% from €5206 to €33,996 per QALY
gained. Although there was a considerable impact on the
point estimate of the ICER for all scenarios considered,
the probability of EuroFIT being cost-effective compared
with no intervention changed less. When assuming one-
year effects of EuroFIT, the probability was 0.47 at a
threshold of €22,000 per QALY gained, when using a
healthcare perspective the probability was 0.57, and
when modelling a time horizon of 10 years the
probability was 0.63 (Fig. 3). In the scenario using litera-
ture utilities, the probability that EuroFIT is cost-
effective compared to no intervention was 0.75 at a
threshold of €22,000 per QALY gained (Fig. 3).
Discussion
In this study, we evaluated the long-term cost-
effectiveness of EuroFIT compared to no intervention
from a societal perspective. EuroFIT was slightly more
effective and slightly more expensive than no interven-
tion, resulting in an ICER of €5206 per QALY gained.
Although this point estimate of the ICER lies well below
the commonly accepted thresholds of between €22,000
to €34,000 per QALY gained, the probability of cost-
Fig. 3 Cost-effectiveness acceptability curves for the base case analysis and the scenario analyses
Fig. 4 Tornado diagram showing the change in incremental cost-effectiveness ratios between the base case analysis and the scenario and
deterministic sensitivity analyses
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effectiveness at these thresholds was only 56 to 58%.
Using a 10-year time horizon and assuming 1 year ef-
fects of EuroFIT had the largest impact on the ICER
point estimates. However, the change in the probability
of cost-effectiveness was largest in the scenario where
utility values from the literature were used for the three
physical activity levels. Given this evidence, we consider
the EuroFIT intervention not to be cost-effective com-
pared to no intervention on a time horizon of 5 years,
but cost-effective on a time horizon of 10 years.
When interpreting the findings of the current study, it
is important to consider the fact that at baseline already
72% of the participants were at recommended levels of
activity. Since we modelled only effects on physical activ-
ity in the current study, this leaves little room for im-
provement. However, EuroFIT resulted in considerable
improvements in other outcomes, such as weight and
biomarkers of cardiometabolic health, as well [20]. As
these improvements might also positively impact health
benefits, it is likely that our study underestimates the
cost-effectiveness of the intervention.
The utility values derived from the EuroFIT RCT were
similar for the three levels of physical activity. In
addition, utility values reported by the EuroFIT RCT
participants in all three physical activity states were
around 0.90, suggesting that the participants had high
quality of life already. This is in contrast with utility
values reported in previous studies, which have shown
that the individuals following the recommended guide-
lines for physical activity have increased utility values
[65–67]. This might reflect problems with the con-
struct validity of the EQ-5D-5 L in the population in-
vestigated. That is, the EQ-5D-5 L might miss
important dimensions relevant to assess health bene-
fits resulting from behavioural interventions, examples
of which can be energy, vitality, enthusiasm, sleeping,
relationships and satisfaction. Using multi-attribute
approaches that include such domains, as suggested
by Wildman and Wildman may prove to be helpful
when evaluating complex interventions like EuroFIT
[65, 68].
Our findings are in line with previous studies evaluat-
ing the cost-effectiveness of intervention programs tar-
geted to improve physical activity. For example, a
systematic review showed that primary care and the
community interventions, such as pedometers as motiv-
ational tools, motivational interviews, brief advice, GP
prescription and GP counselling, appeared to be cost-
effective, with ICERs ranging between €1161 and €16,
666 per QALY gained [31, 67]. The ICER of €5206 per
QALY gained we found in the current study compares
very well with these estimates.
This study has a number of important strengths. It
employed a previously used Markov model24,27 and
extended it with a health state for depression. This al-
lows for a broader assessment of the effects and costs as-
sociated with physical inactivity compared to previous
studies. Moreover, a large number of alternative scenar-
ios was evaluated using probabilistic sensitivity analyses,
which allowed for an in-depth exploration of the uncer-
tainty in assumptions and parameters used in the model.
Finally, whenever possible, parameter estimates were se-
lected from published meta-analyses to avoid the sugges-
tion of “cherry-picking”.
Despite these strengths, the study also has some limi-
tations. Although the most prevalent conditions associ-
ated with a lack of physical activity were included in the
model, a number of other conditions have not been in-
cluded (e.g. hypertension). We expect that this has led to
an underestimation of the cost-effectiveness of the inter-
vention rather than an overestimation. Also, it was not
possible to have more than one disease at the same time
in the model, whereas having for example diabetes in-
creases the risk of cardiovascular disease as well. This
was a pragmatic choice to keep the model as simple as
possible. We expect that taking these comorbid risks
into account could increase the potential cost-
effectiveness of the intervention. In addition, there is a
risk of double-counting the risk of mortality, as part of
the mortality in the different physical activity states is
probably associated with one of the five diseases in-
cluded in the model. However, we expect that this effect
is limited considering the relatively low risk of mortality
for the different levels of physical activity compared to
the mortality risks associated with the different health
conditions included in the model. Finally, we assumed
that the benefits of the intervention were sustained over
the five-year period. Although empirical evidence on the
sustainability of health behaviour changes is limited,
studies indicate that interventions that target both phys-
ical activity and diet, are more likely to result in long-
term changes in health behaviours [32, 68]. Moreover,
results from the FFIT RCT, on which EuroFIT was
based, showed that lifestyle changes were maintained
over 3.5 years [18]. However, since we do not have reli-
able evidence on the retention of the changes in physical
activity, we decided to limit the time horizon of the
model to 5 years. When we assumed that effects dis-
appear after 1 year, the ICER increased greatly (+ 553%).
However, when we increased the time horizon to 10
years the ICER was considerably lower (− 233%).
Despite these limitations, this study is one of the first
evaluating the longer-term cost-effectiveness of a novel
lifestyle intervention that focussed on increasing physical
activity and was tailored to men specifically. Further re-
search should identify whether the EQ-5D-5 L is suitable
to measure quality of life in relatively healthy men; data
from the EuroFIT RCT suggests that its descriptive
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nature was not sensitive enough to distinguish between
different levels of physical activity. Finally, longitudinal
studies should show whether and to which extent effects
on physical activity are sustained beyond the time hori-
zon commonly employed in RCTs to better estimate
long-term cost-effectiveness of interventions aimed at
improving physical activity.
Based on the current study, we conclude the EuroFIT
intervention not to be cost-effective compared to no
intervention over a period of 5 years from a societal per-
spective. However, when using a time horizon of 10
years the results suggest that EuroFIT is more effective
and less expensive compared to (i.e. dominant over) no
intervention. We thus suggest that EuroFIT can poten-
tially improve public health in a cost-effective manner in
the long term.
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